Dr. Lui Franciosi reports

VERITAS EXTENDS WARRANTS

Veritas Pharma Inc. has agreed to amend the terms of share purchase warrants originally issued in February, 2017.

Each warrant will entitle the holder to purchase one share at an exercise price of 40 cents per warrant share. Originally, the warrants were to expire on Feb. 7, 2018; under the amended terms, the warrants will be exercisable until Aug. 7, 2019. The warrants remain subject to an acceleration feature, such that, in the event that the closing price (or closing bid, if no sales were reported on a trading day) of the company's shares as quoted on the Canadian Securities Exchange (or such other securities exchange, quotation system or market on which the shares are listed and where a majority of the trading volume of the shares occurs) exceeds 80 cents per share for a price of 10 consecutive trading days, the company may, within five days of such event, provide notice by way of news release of early expiry, in which event the warrants will expire 30 days from the date of such news release.

About Veritas Pharma Inc.

Veritas Pharma is an emerging-stage pharmaceutical and intellectual property development company, which, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the company's aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and posttraumatic stress disorder, solving the critical need for clinical data to support medical marijuana claims.